Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...
Managed Healthcare Executive4d
FDA Accepts Alvotech/Teva’s Application for Eylea Biosimilar
So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...
ophthalmologytimes3d
Alvotech and Teva Pharmaceuticals announce FDA accepts Biologics License Application for AVT06
Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics ...
Contract Pharma4d
FDA Accepts Alvotech’s Eylea Biosimilar for Review
The U.S. Food and Drug Administration (FDA) has approved for review a Biologics License Application (BLA) for AVT06, Alvotech ...
Business Wire3d
Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars
Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® ...
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea
Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 ...
Why Regeneron's Price May Soon Break Out
Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...
The Pharma Letter2d
New batch of EC nods for Celltrion biosimilars
South Korea-based Celltrion today announced that the European Commission (EC) has granted marketing authorization for three ...
GlobalData on MSN4d
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...
Le Lézard3d
Philips proposes new Supervisory Board appointments and reappointments, and Board of Management reappointment
Mr David Pyott to retire from Philips' Supervisory Board after his third consecutive term.Mr Bob White proposed as new member of the Supervisory Board.Ms Indra Nooyi and Ms Chua Sock Koong proposed ...
Le Lézard4d
Five Ways to Support Better Health on Global Omega-3 Day (March 3)
Are you getting enough of the 'good fats' your body needs to stay healthy? Probably not! EPA and DHA omega-3s, nutrients found naturally in fatty fish and marine microalgae, are important for every ...